Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 9/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | HTT | P42858 | 3/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.60 |
| ▸ | NPY1R | P25929 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.50 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7158449 | 0.98 | HPGD (0.58) | HPGDKDM4EALDH1A1MAPTHTT | |
| SCHEMBL7159726 | 0.90 | ALDH1A1 (0.58) | HPGDKDM4EALDH1A1MAPTHTT | |
| SCHEMBL7158443 | 0.86 | MAPKAPK2 (0.67) | HPGDKDM4EALDH1A1MAPTHTT | |
| SCHEMBL7587711 | 0.85 | MAPT (0.49) | HPGDKDM4EALDH1A1MAPTHTT | |
| Hydrochloric Acid SCHEMBL7162377 | 0.84 | MAPKAPK2 (0.65) | HPGDKDM4EALDH1A1MAPTHTT | |
| SCHEMBL7158128 | 0.83 | NPBWR1 (0.48) | HPGDKDM4EALDH1A1MAPTHTT | |
| SCHEMBL7157877 | 0.80 | NPBWR1 (0.49) | HPGDKDM4EALDH1A1MAPTHTT | |
| SCHEMBL7257324 | 0.80 | NPBWR1 (0.49) | HPGDKDM4EALDH1A1MAPTHTT | |
| Hydrochloric Acid SCHEMBL7159814 | 0.79 | NPBWR1 (0.48) | HPGDKDM4EALDH1A1MAPTHTT | |
| 4-Chloroaniline SCHEMBL7249657 | 0.78 | ALDH1A1 (0.54) | HPGDKDM4EALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232841-A1 | Heterocyclic carboxamides | PFIZER INC | 2003-12-18 | — | — | US | claimed |
| EP-0957099-B1 | Heterocyclic carboxamides | PFIZER PROD INC (US) | 2002-11-20 | — | — | EP | claimed |
| US-20020049211-A1 | Combination treatment for depression and anxiety | SOBOLOV-JAYNES SUSAN BETH (US) | 2002-04-25 | — | — | US | claimed |
| EP-1186318-A2 | Combination, for treating depression and anxiety, containing a 5HT1d receptor antagonist and aCNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | claimed |
| US-20020002168-A1 | Heterocyclic carboxamides | HOWARD HARRY R (US) | 2002-01-03 | — | — | US | claimed |
| US-20010041705-A1 | Heterocyclic carboxamides | HOWARD HARRY R (US) | 2001-11-15 | — | — | US | claimed |
| US-6277852-B1 | FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC | 2001-08-21 | — | — | US | claimed |
| EP-0957099-A2 | Heterocyclic carboxamides | Pfizer Products Inc. (US) | 1999-11-17 | — | — | EP | claimed |
| JP-11322711-A | — | — | None | — | — | JP | disclosed |
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| US-20030232841-A1 | Heterocyclic carboxamides | PFIZER INC | 2003-12-18 | — | — | US | disclosed |
| US-6602874-B2 | 5-(2-(4-methylpiperazin-1-yl)-phenyl)- furan-2-carboxylic acid 4-chlorobenzylamide, for example; treating or preventing migraine, depression and other disorders for which a 5-HT1, agonist or antagonist is indicated | PFIZER INC. | 2003-08-05 | — | — | US | disclosed |
| US-6537995-B2 | Selective serotonin receptor agonists and antagonists used to treat migraines, depression, anxiety and schizophrenia; sertraline | PFIZER INC. | 2003-03-25 | — | — | US | disclosed |
| EP-0957099-B1 | Heterocyclic carboxamides | PFIZER PROD INC (US) | 2002-11-20 | — | — | EP | disclosed |
| EP-1186318-A2 | Combination, for treating depression and anxiety, containing a 5HT1d receptor antagonist and aCNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| US-20020002168-A1 | Heterocyclic carboxamides | HOWARD HARRY R (US) | 2002-01-03 | — | — | US | disclosed |
| US-20010041705-A1 | Heterocyclic carboxamides | HOWARD HARRY R (US) | 2001-11-15 | — | — | US | disclosed |
| US-6277852-B1 | FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC | 2001-08-21 | — | — | US | disclosed |
| JP-H11322711-A | HETEROCYCLIC CARBOXAMIDE | PFIZER PROD INC | 1999-11-24 | — | — | JP | disclosed |
| EP-0957099-A2 | Heterocyclic carboxamides | Pfizer Products Inc. (US) | 1999-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002168-A1 | Heterocyclic carboxamides | HTR1A, HTR1D, NPY1R | HPGD 691/4885KDM4E 1133/4885ALDH1A1 1831/4885 |
| US-20020049211-A1 | Combination treatment for depression and anxiety | HTR1A, HTR1D, HTR5A | HPGD 1917/4885KDM4E 2074/4885ALDH1A1 534/4885 |
| US-20030232841-A1 | Heterocyclic carboxamides | HTR1A, HTR1D, NPY1R | HPGD 691/4885KDM4E 1133/4885ALDH1A1 1831/4885 |
| US-20010041705-A1 | Heterocyclic carboxamides | HTR1A, HTR1D, NPY1R | HPGD 691/4885KDM4E 1133/4885ALDH1A1 1831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.